An Updated Systematic Review and Meta-analysis on Antibiotic Resistance in Iran (2013-2020)
Overview
Authors
Affiliations
This updated systematic review and meta-analysis follows two aims: 1) to assess antibiotic resistance in Iran from 2013 to 2020 and, 2) to assess the trend of resistance from 1999 to 2020. Several national and international databases were systematically searched through MeSH extracted keywords to identify 41 published studies addressing drug-resistant in Iran. Meta-analysis was done based on the PRISMA protocols using Comprehensive Meta-Analysis software. The average prevalence of resistance to first- and second-line anti-TB drugs, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in new and previously treated tuberculosis (TB) cases in Iran during 2013-2020 were as follows: isoniazid 6.9%, rifampin 7.9%, ethambutol 5.7%, pyrazinamide 20.4%, -aminosalicylic acid 4.6%, capreomycin 1.7%, cycloserine 1.8%, ethionamide 11.3%, ofloxacin 1.5%, kanamycin 3.8%, amikacin 2.2%, MDR-TB 6.3% and XDR-TB 0.9%. Based on the presented data, resistance to first- and second-line anti-TB drugs, as well as MDR-TB, was low during 2013-2020 in Iran. Furthermore, there was a declining trend in TB drug resistance from 1999 to 2020. Hence, to maintain the current decreasing trend and to control and eliminate TB infection in Iran, continuous monitoring of resistance patterns is recommended.
Soliman M, Hansen C, Hanafy M, Shawky S, Rashed H, Abdullah M Sci Rep. 2024; 14(1):20401.
PMID: 39223176 PMC: 11369133. DOI: 10.1038/s41598-024-70199-8.
Rastegar M, Nazar E, Nasehi M, Sharafi S, Fakoor V, Shakeri M Infect Dis Model. 2024; 9(3):963-974.
PMID: 38873589 PMC: 11169078. DOI: 10.1016/j.idm.2024.05.003.
Abbasian S, Heidari H, Tadi D, Kardan-Yamchi J, Taji A, Darbandi A J Clin Tuberc Other Mycobact Dis. 2024; 35:100430.
PMID: 38560029 PMC: 10981085. DOI: 10.1016/j.jctube.2024.100430.
Lin K, Xiang L Risk Manag Healthc Policy. 2024; 17:727-737.
PMID: 38559871 PMC: 10981374. DOI: 10.2147/RMHP.S448706.
Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis.
Hosseinali Z, Mohammadshahi J, Teimourpour A, Habibzadeh S, Esmaelizad M, Arzanlou M Mol Biol Rep. 2023; 50(12):10271-10275.
PMID: 37971566 DOI: 10.1007/s11033-023-08867-7.